ArticleAdvances in therapy2023

Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States".

Steven SorscherPubMed ↗Publisher ↗

No numbers read from the abstract.